Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by biopsy or imaging, at a stage classified as BCLC B or C, where curative surgery or a liver transplant is not an option
• People who have at least one tumour that can be measured on scans according to standard criteria (called RECIST)
• People whose treating doctor has determined them suitable for a combination of two medicines: atezolizumab and bevacizumab
• People whose radiation specialist has assessed them as a candidate for a specialised type of radiation treatment called carbon ion radiotherapy
• People whose liver is functioning at a level classified as Child-Pugh class A (a measure of liver health)
• People with a general health and activity level rated as ECOG 0 or 1 (meaning largely or fully active day-to-day)
• People whose blood counts and organ function meet specific minimum levels, including white blood cells, platelets, haemoglobin, kidney function, liver enzyme levels, and bilirubin
• People who either have no uncontrolled varicose veins in the oesophagus or stomach (confirmed by a camera test within the past 6 months), or have had those veins adequately treated before joining
• People who are willing and able to read, understand, and sign a consent form for the study

Who may not be able to join:

• People who have received certain cancer medicines (anti-PD-1, anti-PD-L1, or anti-VEGF therapies) within the past year
• People who have previously had carbon ion radiotherapy to the same area of the body being treated
• People with serious or uncontrolled heart conditions, including a heart attack within the past 6 months, uncontrolled high blood pressure, or severe heart failure (NYHA class III or IV)
• People with an active autoimmune disease (where the immune system attacks the body) that requires ongoing medication to suppress the immune system, or a history of such a condition
• People with an active, uncontrolled infection, including bacterial, viral, or fungal infections, active tuberculosis, HIV, or hepatitis B or C with viral levels that are not under control
• People with a significant risk of bleeding, including active gastrointestinal bleeding, untreated or high-risk varicose veins in the digestive tract, or a blood-clotting problem that cannot be managed with standard treatment
• People with a specific type of blood clot in the main vein of the liver (portal vein tumour thrombosis, grade Vp4) that the study doctor considers unsuitable for treatment
• People who are pregnant or breastfeeding
• People who have previously had any organ transplant, including a liver transplant
• People with any other condition that the study doctor considers likely to affect safe or full participation in the trial

Important: Always verify eligibility with the trial site directly before applying.